1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
General Biologicals Corporation

General Biologicals Corporation

4117.TWO
General Biologicals CorporationTW flagTaipei Exchange
10.50
TWD
- -
- -
628.15MMarket Cap
General Biologicals Corporation
4117.TWO
(Taipei Exchange)

Recent

price

10.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
6.53
6.08
6.77
7.35
5.78
4.67
5.08
5.05
6.37
5.87
9.02
9.22
6.19
4.42
4.07
- -
Revenue per Share
0.25
0.27
0.62
0.24
-0.9
-2.27
-2.37
-2.19
-1.81
-0.96
1.18
0.74
-0.89
-3.32
-3.57
- -
Basic EPS, GAAP
0.36
0.22
1.51
0.88
-1.52
-2.24
-2.62
-1.82
-1.36
-0.12
0.39
-1.44
-0.39
-3.33
-27.68
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.9
4.89
5.78
9.35
6.47
3.97
4.58
3.3
1.44
0.49
5.34
10.74
9.79
6.46
2.84
- -
Book Value per Share
5.33
4.33
4.73
12.34
9.1
5.54
3.59
2.86
1.76
1.17
11.85
11.19
10.55
7.34
3.75
- -
Tangible Book Value per Share
28
28
26
27
34
36
36
37
38
41
53
60
60
60
62
- -
Basic Weighted Avg Shares
184
171
177
195
199
168
185
188
244
240
476
552
370
265
252
216
Sales/Revenue/Turnover
1.36
-4.61
-2.01
-0.79
-15.44
-49.6
-49.47
-48.13
-21.82
-15.79
13.26
5.08
-12.03
-65.63
-84.61
-101.22
Operating Margin (%)
17
17
18
19
20
25
29
21
26
32
31
36
36
37
38
79
Depreciation Expense
7
8
16
6
-31
-82
-86
-81
-69
-39
62
44
-53
-199
-221
466
Net Income, GAAP
- -
- -
- -
35.78
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.05
Effective Tax Rate (%)
3.77
4.38
9.22
3.29
-15.5
-48.68
-46.72
-43.29
-28.39
-16.29
13.06
8
-14.36
-75.08
-87.65
215.93
Profit Margin (%)
69
41
71
283
236
139
49
31
4
-8
524
433
453
-627
61
396
Working Capital
9
- -
- -
- -
- -
- -
- -
17
26
72
51
438
452
379
2,101
2,369
LT Debt
156
134
154
357
340
261
180
164
100
72
688
735
693
497
286
872
Total Equity
- -
- -
- -
-0.36
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-6.73
Return on Invested Capital (%)
- -
- -
- -
4.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
16.94
Return on Capital (%)
5.16
5.44
11.27
3.21
-13.08
-44.74
-55.79
-56.24
-77.87
-104.13
41.17
9.55
-8.66
-40.89
-78.55
101.69
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
88.49%
27.01%
204.54%
Free Cash Flow
19.59%
167.25%
-82.31%
Net Income, GAAP
-59.33%
-55.12%
-310.96%
Sales/Revenue/Turnover
7.38%
-12.93%
-14.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
265
2024
- -
- -
- -
- -
252
2025
- -
- -
- -
- -
216

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-3.32
2024
- -
- -
- -
- -
-3.57
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
Strategic Global Investments, Inc. (STBV)
EPS Bio Technology Corp. (4183.TWO)
Virtuoso Optoelectronics Limit (VOEPL.BO)
Spectral AI, Inc. (MDAI)
Axogen, Inc. (0HKD.L)
Business
General Biologicals Corporation (TWSE: 4117), founded in 1984 and headquartered in Hsinchu Science-Based Park, Taiwan, develops, manufactures and markets in-vitro diagnostics, precision medicine solutions, biopharmaceuticals and consumer healthcare products serving hospitals, laboratories, blood banks and clinics in over 40 countries across Asia, North America, the Middle East and South America. Its core offerings encompass immunoassay technologies including ELISA and chemiluminescence immunoassay (CLIA) systems such as the CL i120 analyzer and reagents for infectious diseases, hepatitis (A/B/C/D), HIV blood screening, tumor markers, thyroid function, hormones, cytokines, cardiac biomarkers and fertility testing; molecular diagnostics via the GBC AIO M160 all-in-one nucleic acid extraction, amplification and analysis platform with RealQuant kits for HBV, HCV and HPV; liquid biopsy technologies under the CellBio brand featuring iFiltration systems like FX10 and a2000 for circulating tumor cell (CTC) detection, monitoring and oncology applications; contract development and manufacturing organization (CDMO) services; blood screening and biomaterial solutions including antibodies and antigens; and P113 antimicrobial peptide pharmaceuticals for oral candidiasis, gingivitis and consumer products under the oh care brand covering oral care, feminine hygiene, baby care, skin care and pet applications. Subsidiaries and affiliates include CurieMed for diagnostic services in Taiwan, Danner Laboratory in the USA for clinical testing, Pacgen Life Science in Canada, GB GENES and DGBC in China. Recent developments feature the May 2025 commissioning of the GBC AI Biotech Building in Hsinchu's AI Smart Park as a hub for nine specialized centers in molecular diagnostics, precision medicine, protein drug R&D, stem cell culture and AI-driven digital pathology; TFDA approval and EU IVDR pursuit for the CL i120 CLIA analyzer driving equipment-plus-reagent sales; multiple CellBio awards including 2025 Taiwan Excellence, SNQ National Quality and National Pharmaceutical Technology Bronze; a three-year exclusive distribution deal with a Brazilian partner for ELISA, CLIA, PCR and hepatitis assays targeting South American blood centers and labs; expanded Fubon Life Insurance CTC testing collaboration exceeding 25,000 cases; and U.S. market launch of CellBio CTC products at AACC 2023 with ongoing global exhibitions.